In Patients With Diabetes, Metformin is Linked to Improved Outcomes in Patients With HER2-Positive, Hormone-Receptor-Positive Breast Cancer

An analysis of data from the ALTTO study suggests that women with diabetes treated with metformin who have been diagnosed with HER2-positive, hormone-receptor-positive breast cancer have better outcomes, including overall survival, than similar women who were not treated with metformin.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.